Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug826 | Caffeine 200 mg Wiki | 1.00 |
| drug3059 | Pravastatin 40 mg Wiki | 1.00 |
| drug2369 | Metoprolol 100 mg Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is an open-label, single sequence study that is being conducted to investigate the potential drug-drug interaction (DDI) when GSK3640254 is co-administered with a cocktail of cytochrome P450 (CYP) enzymes and transporter probe substrates in healthy participants. This study will aid in understanding these interactions and resulting changes in exposure (if any) when drugs that are metabolized via these pathways are given in combination with GSK3640254. The study will consist of a Screening period and 3 sequential treatment regimens. Participants will be administered a single dose of probe substrate drugs (caffeine 200 milligram (mg), metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg and pravastatin 40 mg) on Day 1, followed by washout of 10 days. Participants will then receive GSK3640254 200 mg once daily on Days 11 to 20 followed by co-administration of probe substrate drugs with GSK3640254 on Day 21. The total duration of the study will be approximately 54 days including Screening. Approximately 20 participants will be treated in the study.
Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of caffeine.
Measure: Area under the plasma concentration-time curve (AUC) from time zero to time t (AUC[0-t]) for caffeine Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of caffeine.
Measure: AUC from time zero extrapolated to infinity (AUC[0-inf]) for caffeine Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of caffeine.
Measure: Maximum observed concentration (Cmax) for caffeine Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of caffeine.
Measure: Time of maximum observed concentration (Tmax) for caffeine Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of caffeine.
Measure: Apparent terminal phase half-life (t1/2) for caffeine Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Measure: AUC(0-t) for metoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Measure: AUC(0-inf) for metoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Measure: Cmax for metoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Measure: Tmax for metoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Measure: t1/2 for metoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of montelukast.
Measure: AUC(0-t) for montelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of montelukast.
Measure: AUC(0-inf) for montelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of montelukast.
Measure: Cmax for montelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of montelukast.
Measure: Tmax for montelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of montelukast.
Measure: t1/2 for montelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Measure: AUC(0-t) for flurbiprofen Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Measure: AUC(0-inf) for flurbiprofen Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Measure: Cmax for flurbiprofen Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Measure: Tmax for flurbiprofen Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Measure: t1/2 for flurbiprofen Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Measure: AUC(0-t) for omeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Measure: AUC(0-inf) for omeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Measure: Cmax for omeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Measure: Tmax for omeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Measure: t1/2 for omeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of midazolam.
Measure: AUC(0-t) for midazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of midazolam.
Measure: AUC(0-inf) for midazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of midazolam.
Measure: Cmax for midazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of midazolam.
Measure: Tmax for midazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of midazolam.
Measure: t1/2 for midazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of digoxin.
Measure: AUC(0-t) for digoxin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of digoxin.
Measure: AUC(0-inf) for digoxin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of digoxin.
Measure: Cmax for digoxin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of digoxin.
Measure: Tmax for digoxin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of digoxin.
Measure: t1/2 for digoxin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Measure: AUC(0-t) for pravastatin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Measure: AUC(0-inf) for pravastatin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Measure: Cmax for pravastatin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Measure: Tmax for pravastatin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Measure: t1/2 for pravastatin Time: Day 1 to Day 26Description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Measure: Number of participants with adverse events (AEs) Time: Day 1 to Day 26Description: SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement.
Measure: Number of participants with serious adverse events (SAEs) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Absolute values of platelets, white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils, and basophils (Giga cells per Liter) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Absolute values of absolute neutrophil count Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Absolute values of hematocrit Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Absolute values of hemoglobin (Hgb) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Absolute values of Red blood cell (RBC) count Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Absolute values of Mean corpuscular volume (MCV) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Absolute values of Mean corpuscular hemoglobin (MCH) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Absolute values of blood urea nitrogen (BUN), sodium, glucose (fasting), potassium, phosphorus, calcium, chloride and carbon dioxide (Millimoles per Liter) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Absolute values of anion gap Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Absolute values of total cholesterol Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Absolute values of triglycerides Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Absolute values of creatinine, direct bilirubin, total bilirubin, and uric acid (Micromoles per Liter) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Absolute values of albumin, globulin and total protein (Grams per Liter) Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Absolute values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), lipase, amylase, lactate dehydrogenase (LDH) and creatinine phosphokinase (International Units per Liter) Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine specific gravity Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine potential of hydrogen (pH) Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine glucose Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine protein Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine blood Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine ketones Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine bilirubin and nitrite (Milligrams per deciliter) Time: Day 1 to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Absolute values of urine leukocyte esterase by dipstick Time: Day 1 to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Change from Baseline in platelets, WBC count, neutrophils, lymphocytes, monocytes, eosinophils, and basophils (Giga cells per Liter) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Change from Baseline in absolute neutrophil count (10^9 per Liter) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Change from Baseline in hematocrit Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Change from Baseline in Hgb Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Change from Baseline in RBC count Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Change from Baseline in MCV Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Change from Baseline in MCH Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Change from Baseline in BUN, sodium, glucose (fasting), potassium, phosphorus, calcium, chloride and carbon dioxide (Millimoles per Liter) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Change from Baseline in anion gap Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Change from Baseline in total cholesterol Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Change from Baseline in triglycerides Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Change from Baseline in creatinine, direct bilirubin, total bilirubin, and uric acid (Micromoles per Liter) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Change from Baseline in albumin, globulin and total protein (Grams per Liter) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected for the assessment of clinical chemistry parameters.
Measure: Change from Baseline in ALT, AST, ALP, GGT, creatinine phosphokinase, lipase, amylase, and LDH (International Units per Liter) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine specific gravity Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine pH Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine glucose Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine protein Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine blood Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine ketones Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine bilirubin and nitrite (Milligrams per deciliter) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Urine samples will be collected for the assessment of urine parameters.
Measure: Change from Baseline in urine leukocyte esterase by dipstick Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 10 minutes using an automated ECG machine. PR, QRS, QT, and QTcF intervals will be measured.
Measure: Absolute values of electrocardiogram (ECG) parameters: PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) (Milliseconds) Time: Day 1 to Day 26Description: Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 10 minutes using an automated ECG machine. PR, QRS, QT, and QTcF intervals will be measured.
Measure: Change from Baseline in ECG parameters: PR, QRS, QT, and QTcF (Milliseconds) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Temperature will be assessed using an automated device.
Measure: Absolute values of oral temperature Time: Day 1 to Day 26Description: Temperature will be assessed using an automated device.
Measure: Change from Baseline in oral temperature Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Pulse rate will be assessed in the supine position with a completely automated device.
Measure: Absolute values of pulse rate Time: Day 1 to Day 26Description: Pulse rate will be assessed in the supine position with a completely automated device.
Measure: Change from Baseline in pulse rate Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Respiratory rate will be assessed in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Measure: Absolute values of respiratory rate Time: Day 1 to Day 26Description: Respiratory rate will be assessed in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Measure: Change from Baseline in respiratory rate Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood pressure will be assessed in the supine position with a completely automated device.
Measure: Absolute values of systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury) Time: Day 1 to Day 26Description: Blood pressure will be assessed in the supine position with a completely automated device.
Measure: Change from Baseline in SBP and DBP (Millimeters of mercury) Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Oxygen saturation of participants will be assessed using pulse oximetry.
Measure: Absolute values of oxygen saturation Time: Day 1 to Day 26Description: Oxygen saturation of participants will be assessed using pulse oximetry.
Measure: Change from Baseline in oxygen saturation Time: Baseline (Day -1, Pre-dose) and up to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254
Measure: AUC(0-t) for GSK3640254 Time: Day 11 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254
Measure: AUC from time zero to the end of the dosing interval at steady state (AUC[0-tau]) for GSK3640254 Time: Day 11 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254
Measure: Cmax for GSK3640254 Time: Day 11 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254
Measure: Plasma concentration at the end of the dosing interval (Ctau) for GSK3640254 Time: Day 11 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254
Measure: Tmax for GSK3640254 Time: Day 11 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of GSK3640254
Measure: t1/2 for GSK3640254 Time: Day 11 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol.
Measure: AUC(0-t) for alpha-hydroxymetoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol.
Measure: AUC(0-inf) for alpha-hydroxymetoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol.
Measure: Cmax for alpha-hydroxymetoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol.
Measure: Tmax for alpha-hydroxymetoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol.
Measure: t1/2 for alpha-hydroxymetoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast.
Measure: AUC(0-t) for 36-hydroxymontelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast.
Measure: AUC(0-inf) for 36-hydroxymontelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast.
Measure: Cmax for 36-hydroxymontelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast.
Measure: Tmax for 36-hydroxymontelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast.
Measure: t1/2 for 36-hydroxymontelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole.
Measure: AUC(0-t) for 5-hydroxyomeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole.
Measure: AUC(0-inf) for 5-hydroxyomeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole.
Measure: Cmax for 5-hydroxyomeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole.
Measure: Tmax for 5-hydroxyomeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole.
Measure: t1/2 for 5-hydroxyomeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam.
Measure: AUC(0-t) for 1-hydroxymidazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam.
Measure: AUC(0-inf) for 1-hydroxymidazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam.
Measure: Cmax for 1-hydroxymidazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis 1-hydroxymidazolam.
Measure: Tmax for 1-hydroxymidazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam.
Measure: t1/2 for 1-hydroxymidazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin lactone.
Measure: AUC(0-t) for pravastatin lactone Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin lactone.
Measure: AUC(0-inf) for pravastatin lactone Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin lactone.
Measure: Cmax for pravastatin lactone Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin lactone.
Measure: Tmax for pravastatin lactone Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis of pravastatin lactone.
Measure: t1/2 for pravastatin lactone Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of Cmax of alpha-hydroxymetoprolol to metoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of AUC(0-inf) of alpha-hydroxymetoprolol to metoprolol Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of Cmax of 36-hydroxymontelukast to montelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of AUC(0-inf) of 36-hydroxymontelukast to montelukast Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of Cmax of 5-hydroxyomeprazole to omeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of AUC(0-inf) of 5-hydroxyomeprazole to omeprazole Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of Cmax of 1-hydroxymidazolam to midazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of AUC(0-inf) of 1-hydroxymidazolam to midazolam Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of Cmax of pravastatin lactone to pravastatin Time: Day 1 to Day 26Description: Blood samples will be collected at the indicated time points for pharmacokinetic analysis
Measure: Ratio of AUC(0-inf) of pravastatin lactone to pravastatin Time: Day 1 to Day 26Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports